Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review

References

• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Cancer incidence and mortality statistics worldwide and by region. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed June 23, 2022.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339–364. doi:10.1159/000327577
   PubMed Web of Science ®Google Scholar
• Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med. 2015;5:a21535. doi:10.1101/cshperspect.a021535
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Department of Medical Administration, National Health and Health Commission of the People’s Republic of China. [Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)]. Zhonghua Gan Zang Bing Za Zhi. 2020;28(2):112–128. Chinese. doi:10.3760/cma.j.issn.1007-3418.2020.02.004
   PubMedGoogle Scholar
• Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001. doi:10.1016/S1470-2045(21)00151-0
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, Phase 2–3 study. Lancet Oncol. 2021;22(7):977–990. doi:10.1016/S1470-2045(21)00252-7
   PubMed Web of Science ®Google Scholar
• Shen L, Zhang Y, Guo Y, et al. 987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC). Ann Oncol. 2020;31:S690–S691. doi:10.1016/j.annonc.2020.08.1103
   Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised Phase III REACH study. Eur J Cancer. 2017;81:17–25. doi:10.1016/j.ejca.2017.05.001
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol. 2021;15:1245–1251. doi:10.1080/17474124.2021.1973431
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs. 2022;31:415–423. doi:10.1080/13543784.2021.1972969
   PubMed Web of Science ®Google Scholar
• Zhang EL, Zhang ZY, Li J, Huang ZY. Complete response to the sequential treatment with regorafenib followed by PD-1 inhibitor in a sorafenib-refractory hepatocellular carcinoma patient. Onco Targets Ther. 2020;13:12477–12487. doi:10.2147/OTT.S284092
   PubMed Web of Science ®Google Scholar
• Harding JJ, Abu-Zeinah G, Chou JF, et al. Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma. J Natl Compr Canc Netw. 2018;16(1):50–58. doi:10.6004/jnccn.2017.7024
   PubMed Web of Science ®Google Scholar
• Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer-Am Cancer Soc. 2011;117(19):4475–4483.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu Y, Ma W, et al. The homogeneity and heterogeneity of occurrence, characteristics, and prognosis in hepatocellular carcinoma patients with synchronous and metachronous bone metastasis. J Cancer. 2022;13(2):393–400. doi:10.7150/jca.65308
   PubMed Web of Science ®Google Scholar
• Han S, Zhang XH, Lv T, Han DH. Skull metastasis from the liver: case report and literature review. World Neurosurg. 2017;108:915–989. doi:10.1016/j.wneu.2017.08.104
   Web of Science ®Google Scholar
• Fukushima M, Katagiri A, Mori T, Watanabe T, Katayama Y. [Case of skull metastasis from hepatocellular carcinoma at the site of skull fracture]. No Shinkei Geka. 2010;38(4):371–377. Japanese.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Huang Z, Chu L, Liang J, et al. H19 promotes HCC bone metastasis through reducing osteoprotegerin expression in a protein phosphatase 1 catalytic subunit Alpha/p38 mitogen-activated protein kinase-dependent manner and sponging microRNA 200b-3p. Hepatology. 2021;74(1):214–232. doi:10.1002/hep.31673
   PubMed Web of Science ®Google Scholar
• Hou R, Wang YW, Liang HF, et al. Animal and cellular models of hepatocellular carcinoma bone metastasis: establishment and characterisation. J Cancer Res Clin Oncol. 2015;141(11):1931–1943. doi:10.1007/s00432-015-1958-6
   PubMed Web of Science ®Google Scholar
• De Simone P, Carrai P, Morelli L, et al. Posttransplant hepatocellular carcinoma metastasis at a skull trauma site. Transplantation. 2005;80(9):1358–1359. doi:10.1097/01.tp.0000179155.90423.dc
   PubMed Web of Science ®Google Scholar
• Han L, Lin X, Yan Q, et al. PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. Oncogene. 2022;41(13):1851–1865. doi:10.1038/s41388-022-02197-x
   PubMed Web of Science ®Google Scholar
• Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled Phase II-III trial. J Clin Oncol. 2021;39(27):3002–3011. doi:10.1200/JCO.21.00163
   PubMed Web of Science ®Google Scholar
• Meng X, Wu T, Hong Y, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):245–253. doi:10.1016/S2468-1253(21)00378-2
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Am J Health Syst Pharm. 2021;78(3):187–202. doi:10.1093/ajhp/zxaa365
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–829. doi:10.1016/j.jhep.2012.06.014
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Ozer M, George A, Goksu SY, George TJ, Sahin I. The role of immune checkpoint blockade in the hepatocellular carcinoma: a review of clinical trials. Front Oncol. 2021;11:801379. doi:10.3389/fonc.2021.801379
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29
   PubMed Web of Science ®Google Scholar
• Sanders K, Thomas A, Isache C, Siddiqi A. A rare case of metastatic hepatocellular carcinoma masquerading as a forehead hematoma. Case Rep Gastrointest Med. 2020;2020:8842936.
   PubMed Web of Science ®Google Scholar
• Sadik KW, Dayoub H, Bonatti H. Superior sagittal sinus tumor eroding through the skull: an unfamiliar presentation of hepatocellular carcinoma and literature review. Case Rep Surg. 2019;2019:5945726. doi:10.1155/2019/5945726
   PubMed Web of Science ®Google Scholar
• Ferraz VR, Vitorino-Araujo JL, Sementilli L, Neto JF, Veiga JC. Lesion in scalp and skull as the first manifestation of hepatocellular carcinoma. Case Rep Neurol Med. 2016;2016:2897048. doi:10.1155/2016/2897048
   PubMedGoogle Scholar
• Kim YS, Moon KS, Lee KH, et al. Spontaneous acute epidural hematoma developed due to skull metastasis of hepatocellular carcinoma: a case report and review of the literature. Oncol Lett. 2016;11(1):741–744. doi:10.3892/ol.2015.3947
   PubMed Web of Science ®Google Scholar
• Subasinghe D, Keppetiyagama CT, Sudasinghe H, Wadanamby S, Perera N, Sivaganesh S. Solitary scalp metastasis – a rare presentation of hepatocellular carcinoma. Ann Surg Innov Res. 2015;9:4. doi:10.1186/s13022-015-0013-2
   PubMedGoogle Scholar
• Susheela SP, Revannasiddaiah S, Basavalingaiah AS, Madabhavi I. Painless lump over the forehead which turned painful: an unusual presentation of hepatocellular carcinoma. BJR Case Rep. 2015;1(2):20150033. doi:10.1259/bjrcr.20150033
   PubMedGoogle Scholar
• Chye CL, Lin KH, Ou CH, Sun CK, Chang IW, Liang CL. Acute spontaneous subdural hematoma caused by skull metastasis of hepatocellular carcinoma: case report. BMC Surg. 2015;15:60. doi:10.1186/s12893-015-0045-x
   PubMed Web of Science ®Google Scholar
• Guo X, Yin J, Jiang Y. Solitary skull metastasis as the first symptom of hepatocellular carcinoma: case report and literature review. Neuropsychiatr Dis Treat. 2014;10:681–686. doi:10.2147/NDT.S58059
   PubMed Web of Science ®Google Scholar
• Azarpira N, Dehghanian A, Safarian A, Kazemi K. Case report of skull metastasis from hepatocellular carcinoma after a liver transplant. Exp Clin Transplant. 2014;12(3):265–268. doi:10.6002/ect.2013.0019
   PubMed Web of Science ®Google Scholar
• Turan I, Yapali S, Ozutemiz O, Karasu Z. Frontal skull metastasis extending through the scalp: initial sign of hepatocellular carcinoma recurrence 5 years after liver transplantation. Transplantation. 2013;95(3):e15–e16. doi:10.1097/TP.0b013e31827c650e
   PubMed Web of Science ®Google Scholar
• Brunetti AE, Popescu O, Silvestris N. Synchronous mandibular and giant parieto-occipital skull metastasis from hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11(2):xxvi. doi:10.1016/j.cgh.2012.08.028
   PubMed Web of Science ®Google Scholar
• Ermis F, Dursun M, Kurt R, Akyuz F. Skull metastasis from hepatocellular carcinoma with hepatitis C. Ann Saudi Med. 2012;32(3):321–322. doi:10.5144/0256-4947.2012.321
   PubMed Web of Science ®Google Scholar
• Goto T, Dohmen T, Miura K, et al. Skull metastasis from hepatocellular carcinoma with chronic hepatitis B. World J Gastrointest Oncol. 2010;2(3):165–168. doi:10.4251/wjgo.v2.i3.165
   PubMed Web of Science ®Google Scholar
• Woo KM, Kim BC, Cho KT, Kim EJ. Spontaneous epidural hematoma from skull base metastasis of hepatocellular carcinoma. J Korean Neurosurg Soc. 2010;47(6):461–463. doi:10.3340/jkns.2010.47.6.461
   PubMed Web of Science ®Google Scholar
• Kanai R, Kubota H, Terada T, Hata T, Tawaraya E, Fujii K. Spontaneous epidural hematoma due to skull metastasis of hepatocellular carcinoma. J Clin Neurosci. 2009;16(1):137–140. doi:10.1016/j.jocn.2008.02.020
   PubMed Web of Science ®Google Scholar
• Shim YS, Ahn JY, Cho JH, Lee KS. Solitary skull metastasis as initial manifestation of hepatocellular carcinoma. World J Surg Oncol. 2008;6:66. doi:10.1186/1477-7819-6-66
   PubMed Web of Science ®Google Scholar
• Hsu SY, Chang FL, Sheu MM, Tsai RK. Homonymous hemianopia caused by solitary skull metastasis of hepatocellular carcinoma. J Neuroophthalmol. 2008;28(1):51–54. doi:10.1097/WNO.0b013e3181675438
   PubMed Web of Science ®Google Scholar
• Hsieh CT, Sun JM, Tsai WC, Tsai TH, Chiang YH, Liu MY. Skull metastasis from hepatocellular carcinoma. Acta Neurochir. 2007;149(2):185–190. doi:10.1007/s00701-006-1071-3
   PubMed Web of Science ®Google Scholar
• Nam SW, Han JY, Kim JI, et al. Spontaneous regression of a large hepatocellular carcinoma with skull metastasis. J Gastroenterol Hepatol. 2005;20(3):488–492. doi:10.1111/j.1440-1746.2005.03243.x
   PubMed Web of Science ®Google Scholar
• Jegou J, Perruzi P, Arav E, Pluot M, Jaussaud R, Remy G. Métastases mixtes cutanéo-osseuses révélatrices d’un carcinome hépatocellulaire [Cutaneous and bone metastases revealing hepatocarcinoma]. Gastroenterol Clin Biol. 2004;28(8–9):804–806. French. doi:10.1016/S0399-8320(04)95132-9
   PubMedGoogle Scholar
• Chan CH, Trost N, McKelvie P, Rophael JA, Murphy MA. Unusual case of skull metastasis from hepatocellular carcinoma. Anz J Surg. 2004;74(8):710–713. doi:10.1111/j.1445-1433.2004.02961.x
   PubMed Web of Science ®Google Scholar
• Torres M, Alvarez R, Lopez D, Tito L. Hepatocellular carcinoma skull metastasis with both extradural and subcutaneous extension. J Hepatol. 2002;36(4):569. doi:10.1016/S0168-8278(02)00033-8
   PubMedGoogle Scholar
• Hayashi K, Matsuo T, Kurihara M, Daikoku M, Kitange G, Shibata S. Skull metastasis of hepatocellular carcinoma associated with acute epidural hematoma: a case report. Surg Neurol. 2000;53(4):379–382. doi:10.1016/S0090-3019(00)00208-1
   PubMedGoogle Scholar
• Nakagawa Y, Yoshino E, Suzuki K, Tatebe A, Andachi H. Spontaneous epidural hematoma from a hepatocellular carcinoma metastasis to the skull – case report. Neurol Med Chir. 1992;32(5):300–302. doi:10.2176/nmc.32.300
   PubMedGoogle Scholar